News | November 23, 2024
Merck recommends rejection of TRC Capital’s “Mini-Tender” Offer
The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024
The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024
The collaboration offers opportunities for training, research fellowships, workshops and conferences at palliative care centers managed by Ajit Isaac Foundation
New research labs and process development services to enable next generation therapeutics
Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory
Emcure has launched an awareness campaign to help spread the word about male anemia
CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
Jagsonpal Pharmaceuticals has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities
The product will be manufactured at Lupin’s Somerset facility in the US
Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US
Subscribe To Our Newsletter & Stay Updated
